Parkinson’s Disease
Parkinson’s disease is a progressive neurological condition that results in a variety of symptoms. Symptoms of Parkinson’s and their severity are different for every person and may cause uncontrolled movements and challenges with balance and coordination.
The exact cause of Parkinson’s is unknown, but research points to a combination of environmental and genetic factors. In some cases, Parkinson’s appears to be associated with a single gene mutation in the DNA of affected individuals. Some of the most common mutations may include mutations in the LRRK2, GBA, and SNCA genes.
A mutation in the LRKK2 gene can lead to overactivity of the LRRK2 protein. This overactivity disrupts the normal functioning of the lysosomes, the special compartments within cells that break down components that are no longer needed. When this function is disrupted, it leads to the build-up of toxic compounds that causes damage to specific brain cells. This damage may lead to the onset of Parkinson’s.
Denali’s scientific approach to Parkinson’s disease
Denali, in partnership with Biogen, is evaluating DNL151, also known as BIIB122, an investigational medication in pill form that may delay the progression of Parkinsons's disease in people who are in the early stage of their condition. DNL151 is proposed to work by reducing the activity of LRRK2 proteins, which in turn may improve the function of lysosomes. It is being studied to determine if this hypothesized effect slows progression of Parkinson’s Disease.
To learn more about this study, including details about who may be eligible, visit the following resources: ClinicalTrials.gov and The LUMA Study
BIIB122/DNL151 is an investigational drug, its clinical profile has not been established, and it has not been approved by any global health authority.
By clicking these links, you will leave the Denali Therapeutics website and be redirected to a third-party site. Denali is not responsible for, nor does it endorse, the content, terms and conditions of use or privacy practices of external websites.
“As a patient and employee (at Denali), I feel that the more we connect our work to the people we are trying to help, the better chance we have of succeeding. Throughout my time here, I’ve experienced Denali’s commitment to bringing meaningful therapies to individuals like me and my family.”
Allan Aks - Person living with Parkinson’s and Senior R&D Finance Director at Denali
Advocacy Organizations
These organizations are committed to the needs of people and families affected by Parkinson’s disease. Their websites may offer you more information, resources, and guidance.
By clicking these links, you will leave the Denali Therapeutics website and be redirected to a third-party site. Denali is not responsible for, nor does it endorse, the content, terms and conditions of use or privacy practices of external websites.
The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today.
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience, and passion of our global Parkinson’s community.
Parkinson’s UK provides information and support to people living with Parkinson’s and funds research into groundbreaking treatments.
Denali values all Parkinson's Disease community members and organizations. Additional resources may be available.
For questions, please contact the Denali Patient Advocacy team at patients@dnli.com.